CRISPR Therapeutics AG

CRISPR‑Therapeutics faces a pivotal patent battle as the PTAB rules in favor of the Broad Institute, threatening its gene‑editing pipeline and investor confidence.

CRISPR Therapeutics AG (CRSP) gains investor optimism as the $8.74 billion gene‑transfer market expands, with analysts backing its cutting‑edge gene‑editing pipeline.